Real-World Studies
First-Line Palbociclib vs Ribociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
Tohumcuoğlu et alMedicina (Kaunas)
This retrospective single-center cohort study evaluated real-world overall survival (OS) and progression-free survival (PFS) among postmenopausal patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer treated with first-line CDK4/6 inhibitors plus letrozole. The cohort comprised 140 patients, including 67 treated with palbociclib/letrozole and 73 treated with ribociclib/letrozole. At a median follow-up of 52.3 months, a total of 93 deaths and 118 progression events occurred across both treatment groups.
No statistically significant differences in survival outcomes were observed between the two regimens. Median OS was 36 months for the palbociclib/letrozole group compared to 29 months for the ribociclib/letrozole group (HR, 1.23; 95% CI, 0.82-1.86; p = 0.322). Median PFS was 15.4 months for palbociclib/letrozole and 16.4 months for ribociclib/letrozole (HR, 1.05; 95% CI, 0.73-1.52; p = 0.778).
The study also examined the prognostic performance of an exploratory composite clinical-inflammatory risk score (CRS) incorporating progesterone receptor expression <20%, presence of visceral metastasis, and baseline pan-immune-inflammation value ≥477.8. Patients with a CRS of 0-1 achieved a median OS of 34 months compared to 30 months for those with a CRS of 2-3 (univariable HR, 1.68; 95% CI, 1.11-2.54; p = 0.014). However, internal validation demonstrated poor discrimination, with apparent and optimism-corrected c-indices of 0.573 and 0.570, respectively. Furthermore, adding the composite score to a clinical model did not significantly enhance model fit (likelihood-ratio p = 0.143).
Key Takeaways
- In a real-world cohort of postmenopausal patients with HR+/HER2- metastatic breast cancer, first-line palbociclib/letrozole and ribociclib/letrozole demonstrated no statistically significant differences in median overall survival (36 vs 29 months; HR, 1.23; 95% CI, 0.82-1.86; p = 0.322) or median progression-free survival (15.4 vs 16.4 months; HR, 1.05; 95% CI, 0.73-1.52; p = 0.778).
- Although a high composite clinical-inflammatory risk score (CRS 2-3) was univariably associated with worse median overall survival compared to a low score (30 vs 34 months; HR, 1.68; 95% CI, 1.11-2.54; p = 0.014), the score showed limited discrimination (optimism-corrected c-index, 0.570) and failed to provide significant incremental prognostic value when added to a clinical model (p = 0.143).
Read the original sourceMedicina (Kaunas)
